To compare the structural changes, clinical course, and treatment outcomes of vertical and horizontal vitreomacular traction (VMT) induced impending macular holes (IMHs) and full-thickness macular ...
An enzyme injected into the vitreous cavity in patients with vitreomacular adhesion may release focal points of contact, thus obviating the need for surgical intervention for relief of vitreomacular ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Hyaloid adhesion occurs regularly in ...
Vitreomacular adhesion can lead to pathologic traction and macular hole. The standard treatment for severe, symptomatic vitreomacular adhesion is vitrectomy. Ocriplasmin is a recombinant protease with ...
- Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for Vitrectomy ThromboGenics NV (Euronext Brussels ...
Vitreomacular adhesion (VMA) can lead to reduced visual acuity, metamorphopsia, photopsia, and micropsia. These symptoms are explained by vitreomacular traction (VMT) at the vitreomacular junction.
The composition of vitreous is 98% water and 2% structural macromolecules. Early in embryonic development, the molecular constituents of vitreous form a clear, gel-like structure that is adherent to ...
LEUVEN, Belgium, December 4, 2007 -- - Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for ...
ThromboGenics' eye drug, Jetrea (ocriplasmin) has been approved in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results